Welcome to our dedicated page for Evotec SE American Depositary Shares news (Ticker: EVO), a resource for investors and traders seeking the latest updates and insights on Evotec SE American Depositary Shares stock.
Evotec SE, headquartered in Hamburg, Germany, is a leading global drug discovery and development company. Specializing in providing comprehensive solutions to pharmaceutical and biotechnology companies, academic institutions, and nonprofit organizations, Evotec is renowned for its extensive capabilities in therapeutic areas such as central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health.
Evotec’s core business is divided into two main segments: Shared R&D and Just-Evotec Biologics. The Shared R&D segment, making up approximately 80% of the company's sales, offers drug discovery and manufacturing services on a fee-for-service basis. It also engages in integrated drug discovery collaborations leveraging proprietary, internally-developed assets. Just-Evotec Biologics, accounting for about 20% of sales, provides contract development and manufacturing (CDMO) services for biologics.
With a workforce of over 5,000 employees, Evotec operates 18 production sites mainly across Europe and the United States. In recent years, the company has made significant strides in forming strategic alliances and collaborations, such as the recent partnership with Claris Ventures and Variant Bio, aimed at accelerating the development of innovative therapeutics.
Evotec’s multimodal platform combines cutting-edge technologies, data, and scientific expertise to drive the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. The company’s integrated R&D network includes partnerships with all Top 20 Pharma companies and over 800 biotech companies, academic institutions, and other healthcare stakeholders. This robust network facilitates the co-creation of a world-leading pipeline of over 200 proprietary and co-owned R&D projects, ranging from early discovery to clinical development.
Recent achievements by Evotec include the successful Clinical Trial Application (CTA) for IAMA Therapeutics’ lead program IAMA-6 and the strategic collaboration with Janssen for immune-based therapies. Additionally, Evotec has expanded its relationship with Bristol Myers Squibb in neurodegeneration and targeted protein degradation.
Financially, Evotec has demonstrated resilience despite macroeconomic challenges and a substantial cyber-attack in 2023. The company reported a 4% increase in revenues, reaching €781.4 million in 2023, driven by new collaborations and the strong performance of Just-Evotec Biologics.
As of 2024, Evotec continues to focus on sustainable and profitable growth, optimizing its operations to meet evolving market demands. The company is committed to advancing its mission of discovering and developing effective therapeutics that address unmet medical needs globally.
Just - Evotec Biologics, a segment of Evotec, has expanded its strategic partnership with Sandoz, focusing on the development and commercial manufacturing of biosimilars. This agreement, announced on July 8, 2024, ensures long-term commercial supply security for Sandoz from Evotec's newly built J.POD® manufacturing facility in Toulouse, France. The extended partnership promises remuneration for early scientific validation and additional funding upon reaching development milestones from 2025. Since May 2023, the collaboration has leveraged Just - Evotec Biologics' data-driven design and continuous manufacturing technology to enhance product quality and cost efficiency. Dr. Matthias Evers, Evotec's Chief Business Officer, highlighted the potential to improve patient access to medicines and validate the strategic establishment of their second J.POD® facility.
Evotec SE's subsidiary, Just - Evotec Biologics, has been selected by the U.S. Department of Defense (DOD) to develop an accelerated monoclonal antibody (
Evotec has announced significant progress in its neuroscience collaboration with Bristol Myers Squibb, earning a $20 million payment as a result of the advancement. The partnership, established in December 2016, aims to discover disease-modifying treatments for neurodegenerative diseases. A target-based programme has now advanced to late pre-clinical development, contributing to an expanding pipeline. The collaboration saw its first success with the in-licensing of EVT8683, now BMS-986419, in September 2021. Following a successful Phase I study, Phase II is set to commence in 2024. In March 2023, the partnership was extended for another 8 years, showcasing their commitment to innovative treatments and patient care.
Evotec SE announced that the majority of proposals put forward at its 2024 Annual General Meeting (AGM) were approved by shareholders. Held on June 10, 2024, the AGM saw the election of Dr. Duncan McHale and Wesley Wheeler to the Supervisory Board, replacing Dr. Elaine Sullivan and Dr. Mario Polywka. Most agenda items, including the 2023 Remuneration Report, received majority approval, except the discharge of the former CEO, Dr. Werner Lanthaler, for the 2023 financial year, which was rejected. Shareholders also agreed to amendments to the Articles of Association and confirmed BDO AG Wirtschaftspruefungsgesellschaft as auditors for 2024. The AGM represented 58.18% of the registered share capital.
Evotec has entered a collaboration with Inserm, Lille University Hospital, and Inserm Transfert to identify new therapeutic targets and markers for obesity and metabolic diseases. This partnership will utilize Evotec's PanOmics technologies to analyze large omics datasets, including transcriptomics, proteomics, and metabolomics, from over 8,000 human samples. Evotec will support the recruitment of 200 additional subjects in the next two years. The data will be integrated into Evotec's E.MPD platform for analysis. The collaboration aims to better understand the molecular mechanisms of metabolic conditions and develop more effective treatments.
Evotec SE has extended its 20-year collaboration with CHDI Foundation, a nonprofit focused on Huntington's disease therapeutics. This alliance leverages Evotec's neuroscience platform and expertise in CNS drug discovery. Initiated in 2006, it remains one of Evotec's largest strategic drug discovery partnerships. The collaboration covers diverse services, including target validation, stem-cell research, and biomarker discovery. Evotec's COO, Dr. Craig Johnstone, expressed pride in their ongoing contributions, while CHDI's CSO, Dr. Robert Pacifici, praised Evotec's role in CHDI's preclinical research programs.
Evotec SE reported its Q1 2024 financial results, revealing a 2% drop in group revenues to €208.7 million. This decline was driven by a 23% reduction in Shared R&D revenues, which fell to €155.2 million due to a challenging market. However, Just - Evotec Biologics saw a remarkable 383% revenue increase to €53.5 million.
Adjusted Group EBITDA significantly decreased to €7.8 million from €34.3 million in Q1 2023, affected by higher costs and lower operating income. The company introduced new reporting segments to simplify its structure and aims to reset for profitable growth.
Evotec's strategic partnerships and new agreements in AI, neuroscience, and IBD therapies contribute to its pipeline. Notable collaborations with Owkin, Bristol Myers Squibb, and the Crohn's & Colitis Foundation were highlighted. Post-period events include new partnerships for fibrosis treatments with Variant Bio and precision cardiology with Bayer.
Corporate updates include a CEO transition to Dr. Mario Polywka and the completion of the closure of its Chemistry activities in Marcy. The full-year 2024 outlook anticipates double-digit revenue growth and mid-double-digit adjusted EBITDA growth.
Evotec SE (NASDAQ: EVO) will announce its first quarter 2024 financial results on May 22, 2024. The company will host a conference call on the same day at 2:00 pm CEST (8:00 am EDT) to discuss the results and provide a performance update. Evotec operates globally in underserved therapeutic areas, including neurology, oncology, metabolic, and infectious diseases. The company has over 200 R&D projects and collaborates with Top 20 Pharma and 800+ biotechnology firms. The webcast and presentation slides will be available on Evotec's investor relations website.
Bayer and Evotec have updated their strategic collaboration to focus on developing innovative precision treatments for cardiovascular diseases. By leveraging Evotec's disease modelling capabilities using human induced pluripotent stem cells (iPSCs), the alliance aims to identify and validate novel targets to build a portfolio of precision cardiology therapeutics. Both companies will contribute drug targets and technology platforms for the development of innovative treatment options. Bayer will handle clinical development and commercialization while sharing responsibilities during pre-clinical development with Evotec. The collaboration seeks to address the high unmet medical need in cardiovascular diseases that are the leading cause of death globally.
FAQ
What is the current stock price of Evotec SE American Depositary Shares (EVO)?
What is the market cap of Evotec SE American Depositary Shares (EVO)?
What is Evotec SE?
What are Evotec's main business segments?
Who are Evotec's partners?
What recent collaborations has Evotec entered into?
How many employees does Evotec have?
What are Evotec's key therapeutic areas?
What financial performance did Evotec report in 2023?
What are the future goals of Evotec?
What is Just-Evotec Biologics?
What makes Evotec's platform unique?
